Day: June 5, 2023

Apollo Funds to Invest $2 Billion in Preferred Equity of AT&T Mobility II LLC

Written by Customer Service on . Posted in Public Companies.

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that, on behalf of its affiliated and third-party insurance clients and other investors, it has agreed to invest $2.0 billion in preferred equity securities to be issued by AT&T Mobility II LLC, a subsidiary of AT&T Inc. (NYSE: T). AT&T Mobility II LLC will use the proceeds from the investment to partially replace the $8 billion of preferred interests that were outstanding prior to the fourth quarter of 2022. The investment, expected to be completed in June 2023, allows Apollo’s insurance and institutional clients to access investment-grade rated securities in one of the nation’s leading wireless businesses. About Apollo Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our...

Continue reading

Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting

Written by Customer Service on . Posted in Public Companies.

Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response not reached despite median follow up of 39 months in TACTI-002 Phase II Promising efficacy in patients with a PD-L1 Combined Positive Score (CPS) of ≥1 with median Overall Survival of 12.6 months, a 12-month Overall Survival rate of 52.0%, and a response rate of 38.5% Patients with a PD-L1 CPS ≥20 achieved a median Overall Survival of 15.5 months, a 12-month Overall Survival rate of 66.7%, and a response rate of 60.0% One long-lasting complete response occurred in a patient with negative PD-L1 expression or CPS 20, overall survival, progression-free survival, and response rates from the dual immuno-oncology approach compare rather favourably to reported results from anti-PD-1 monotherapy approved...

Continue reading

WSP Completes the Acquisition of Calibre

Written by Customer Service on . Posted in Mergers And Acquisitions.

MONTREAL, June 05, 2023 (GLOBE NEWSWIRE) — WSP Global Inc. (TSX: WSP) (“WSP” or the “Corporation”) is pleased to announce that it has completed the acquisition of Calibre Professional Services One Pty Ltd (“Calibre”), in Australia. With the addition of Calibre’s 800 professionals, WSP strengthens its position as a leading provider of services across the full mining asset life cycle. WSP’s mining team now represents over 5,200 professionals globally, including 1,400 experts in Australia, and benefits from an enhanced ability to support blue-chip mining clients in Western Australia. “We are eager to leverage the full potential of our combined teams and work together to support mining clients with strong ESG commitments,” said Alexandre L’Heureux, President and CEO of WSP. “We have the opportunity to play a pivotal role at a time...

Continue reading

SPREE ACQUISITION CORP. 1 LIMITED ANNOUNCES CONTRIBUTIONS TO TRUST ACCOUNT IN CONNECTION WITH PROPOSED EXTENSION

Written by Customer Service on . Posted in Mergers And Acquisitions.

Atlanta, Georgia, June 05, 2023 (GLOBE NEWSWIRE) —  Spree Acquisition Corp. 1 Limited (NYSE: SHAP) (“Spree” or the “Company”) announced today that, in connection with its previously announced extraordinary general meeting in lieu of the 2023 annual general meeting of shareholders of the Company to be held at 9:00 a.m. Eastern Time on Monday, June 12, 2023 (the “Meeting”) for the purpose of considering and voting on, among other proposals, a proposal to extend the date by which the Company must consummate a business combination (the “Articles Extension”) from June 20, 2023 to March 20, 2024 (such nine-month period, the “Extension Period”), or such earlier date as may be determined by the Company’s board of directors, in its sole discretion, the Company’s sponsor, Spree Operandi, LP, and/or its wholly-owned U.S. subsidiary, Spree...

Continue reading

GDS Announces Results of Annual General Meeting of Shareholders and of Additional Meetings of Shareholders

Written by Customer Service on . Posted in Public Companies.

SHANGHAI, China, June 05, 2023 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced that it held its annual general meeting of shareholders of the Company (the “2023 AGM”) on June 5, 2023. The Company also held meetings of the holders of the class A ordinary shares (the “2023 Class A Shareholders Meeting”), the holders of the preferred shares (the “2023 Preferred Shareholders Meeting”) and the holders of the class B ordinary shares (the “2023 Class B Shareholders Meeting”) on June 5, 2023. 2023 AGM Each of the resolutions submitted to the shareholders for approval at the 2023 AGM has been approved. Specifically, the shareholders of the Company passed special resolutions...

Continue reading

Arvinas to Participate in Upcoming Investor Conferences

Written by Customer Service on . Posted in Public Companies.

NEW HAVEN, Conn., June 05, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: Jefferies Healthcare Conference on Thursday, June 8. A live audio webcast of the fireside chat at 11 a.m. ET will be available here and on the Events + Presentations section of the Company’s website. Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12. A live audio webcast of the fireside chat at 5:40 p.m. ET / 2:40 p.m. PT will be available here and on the Events + Presentations section of the Company’s website. About ArvinasArvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from...

Continue reading

Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9

Written by Customer Service on . Posted in Public Companies.

LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST). Conference Call Details:To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call. Webcast Registration link: https://edge.media-server.com/mmc/p/u32tnka9 For further information, please contact: Renalytix plc www.renalytix.com James...

Continue reading

Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Written by Customer Service on . Posted in Public Companies.

PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023 at 3:20 p.m. PT in Dana Point, CA. A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event. About Passage Bio Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases...

Continue reading

NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101

Written by Customer Service on . Posted in Public Companies.

NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets Lotus Pharmaceuticals will acquire worldwide rights for NRX-101 for S-TRBD and will be responsible for commercialization of NRX-101 in markets outside the US through Lotus’s direct presence in certain Asian markets or through their export division, which currently has partnerships in numerous markets, including in Europe, Japan, China, Australia and Latin America Alvogen, through its CNS focused Almatica® division, will be responsible for U.S. commercialization of NRX-101 NRx will be eligible to receive up to $330 million in milestone payments tied to development progress and sales targets as well as tiered double-digit escalating...

Continue reading

EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy

Written by Customer Service on . Posted in Public Companies.

– Significant investigator and patient interest drove strong recruitment of 77 patients exceeding the 60 patient target – – Topline PAVIA data anticipated in 2Q 2024 – WATERTOWN, Mass., June 05, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it has completed enrollment in the Phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential nine-month treatment for moderate to severe non-proliferative diabetic retinopathy (NPDR). “We are delighted to report the completion of enrollment in the Phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential nine-month treatment for NPDR,” said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals. “We are...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.